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Abstract
Computational prediction of drug–target interactions is an essential
task with various applications in the pharmaceutical industry, such as
adverse effect prediction or drug repositioning. Recently, expert sys-
tems based on machine learning have been applied to drug–target inter-
action prediction. Although hubness-aware machine learning techniques
are among the most promising approaches, their potential to enhance
drug–target interaction prediction methods has not been exploited yet.
In this paper, we extend the Bipartite Local Model (BLM), one of the
most prominent interaction prediction methods. In particular, we use
BLM with a hubness-aware regression technique, ECkNN. We represent
drugs and targets in the similarity space with rich set of features (i.e.,
chemical, genomic and interaction features), and build a projection-based
ensemble of BLMs. In order to assist reproducibility of our work as well as
comparison to published results, we perform experiments on widely used
publicly available drug–target interaction datasets. The results show that
our approach outperforms state-of-the-art drug–target prediction tech-
niques. Additionally, we demonstrate the feasibility of predictions from
the point of view of applications.
1
1 Introduction
Due to the large number of drug compounds and pharmacological targets, many
of the interactions between these entities are unknown. More complete knowl-
edge about drug–target interactions will not only contribute to better under-
standing the pharmacology of drugs, but it is also relevant for the prediction of
adverse effects and drug repositioning, i.e., use of an existing medicine to treat
a disease that has not been treated with that drug yet. The relevance of the
later application is also underlined by the fact that only a few dozens of new
drugs are approved by FDA each year. Moreover, the average costs related to
discovery of a new drug are approximately $1.8 billion, and the process takes
more than 10 years [18].
In addition, the incomplete knowledge about the interactions between drugs
and pharmaceutical targets in case of drugs affecting the central nervous system
(CNS) further emphasizes the need for computational prediction approaches:
while CNS plays an essential role, the costs associated with disorders affecting
CNS are enormous: solely in Europe, the total annual costs associated with
brain disorders is estimated to be approximately 800 billion EUR [25].
The biochemical validation of hypothesized drug–target interactions is labo-
rious, time-consuming and expensive [31] [49]. Therefore, computational meth-
ods have been proposed for the prediction of drug–target interactions [5] [22] [23]
[34]. Traditional techniques include approaches based on molecular docking [10]
[15] [29], ligand chemistry [21], [26] and text mining [53].
A serious limitation of docking-based approaches is that they require in-
formation about the three-dimensional structure of candidate drugs and targets
which is often not available, especially for G-protein coupled receptors (GPCRs)
and ion channels. Additionally, the performance of ligand-based approaches de-
crease in case if only few ligands are known.
In response to the above limitations of classic approaches, expert systems
based on machine learning techniques have been proposed for the prediction of
drug–target interactions [14] [50] [51]. Recent approaches are based on matrix
factorization [12] [14] [52], restricted Boltzmann machines [48], network-based
inference [9] [11] [35] [43], positive-unlabeled learning [22] and the integration
of multiple sources of information [33] [42]. See also [32] and [37] for excellent
surveys.
One of the most prominent drug–target interaction prediction techniques is
based on Bipartite Local Models (BLMs) [4] in case of which the drug–target
interaction prediction task is treated as a link prediction problem in bipar-
tite graphs. Recent works aiming to extend BLMs focused on semi-supervised
prediction [50], improved kernels [47] and the incorporation of neighbor-based
interaction-profile inferring [24].
However, none of the aforementioned prediction techniques took the pres-
ence of hubs into account. With hubs, we mean entities that are connected
to surprisingly many other entities of a network. This phenomenon has been
observed for various biological, chemical and medical networks, see e.g. [1] [17].
Similar observations can be made for drug–target networks as well, e.g., Fig.1
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Figure 1: The degree distribution in the Enzyme drug–target network. The
horizontal axis corresponds to the number of interactions, whereas the vertical
axis corresponds to the number of drugs (left) or targets (right). For example,
the first column in the left diagram shows that 177 drugs interact with only one
(but not necessarily the same) target. In contrast, some drugs (and targets,
resp.) participate in surprisingly many interactions, e.g., there are 16 drugs,
each of which interacts with 19 targets.
shows the degree distribution for the drugs and targets in the Enzyme drug–
target interaction network (we will describe the data in Section 2.1). As one can
see, the distributions have long tails, i.e., there are drugs (and targets, resp.)
that are connected with surprisingly many targets (drugs, resp.) compared to
“average” drugs (targets, respectively).
The presence of hubs has been observed in nearest neighbor graphs, see
e.g. [8] [28] [46], and hubness-aware classifiers have been developed, see [45]
for a survey. More recently, hubness-aware regression techniques, including k-
nearest neighbor with error correction (ECkNN), were developed that allow
for predictions on a continuous scale [7]. Despite the fact that hubness-aware
techniques are among the most promising recent machine learning approaches,
their potential to enhance drug–target interaction prediction methods has not
been exploited yet: to the best of our knowledge, our initial work [6] is the
only one aiming to apply hubness-aware models to the drug–target prediction
problem.
In this study, we extend Bipartite Local Models and our previous work [6].
We use ECkNN as local model of BLM and propose an enhanced representa-
tion of drugs and targets in a multi-modal similarity space (i.e., a representa-
tion which incorporates multiple similarity measures). Furthermore, we build
a projection-based ensemble and study how the performance depends on the
number of base models of the ensemble. As we use hubness-aware local mod-
els in the proposed approach, we refer to it as HLM for simplicity. In order
to assist reproducibility of our work as well as comparison to published results,
we perform experiments on publicly available real-world drug–target interaction
datasets. The results show that our approach outperforms other state-of-the-art
drug–target prediction techniques.
The rest of this paper is organized as follows: in Section 2 we review the
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Table 1: Number of drugs, targets and interactions in the datasets used in our
study.
Dataset # Drugs # Targets # Interactions
Enzyme 445 664 2926
Ion Channels 210 204 1476
G-protein coupled receptors (GPCR) 223 95 635
Nuclear Receptors (NR) 54 26 90
Kinase [36] 68 442 1527
background necessary to understand our work. In particular, we focus on BLM
and ECkNN. Section 3 presents the proposed approach, followed by its experi-
mental evaluation in Section 4. Finally, conclusions are drawn in Section 5.
2 Materials and Methods
In order to ensure that the paper is self-contained, we begin this section by
describing the datasets used in our study and the procedure to obtain drug–
drug and target–target similarities. Subsequently, the BLM approach for drug–
target interaction prediction is reviewed. This is followed by the description of
hubness-aware error correction for nearest neighbor regression.
2.1 Drug–Target Interaction Data
In our study we used five publicly available drug–target interaction datasets from
two repositories,1 namely Enzyme, Ion Channel, G-protein coupled receptors
(GPCR), Nuclear Receptors (NR), and Kinase[36]. These datasets have been
used in various studies, see e.g. [4] [14] [50], [51] and [39].
Each of the first four datasets contains a binary interaction matrix between
drugs and targets, in which each entry indicates whether the interaction between
the corresponding drug and target is known or not. In contrast, Kinase contains
continuous values of binding affinity for all drug–target pairs of the data. In
order to produce a binary interaction matrix, we used the same cutoff threshold
as Pahikkala et al. [39]. Tab. 1 shows the number of drugs, targets and
interactions in the datasets.
In general, drug–drug and target–target similarities may be computed in
many ways. Next, we describe the similarities used in our study. In case of the
Enzyme, Ion Channel, GPCR and NR datasets, chemical structure similarities
were computed using the SIMCOMP [16] graph-alignment algorithm, in order
to obtain drug–drug similarities. For Kinase, we used 2D Tanimoto coefficients
as drug–drug similarities.
1http://web.kuicr.kyoto-u.ac.jp/supp/yoshi/drugtarget/
http://staff.cs.utu.fi/~aatapa/data/DrugTarget/
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Figure 2: Bipartite Local Models for the prediction of drug–target interactions.
In order to compute the similarity between target proteins of the Enzyme,
Ion Channel, GPCR and NR datasets, their amino acid sequences were retrieved
from the KEGG GENES [20] database so that similarities between pharmaco-
logical targets were determined by sequence alignment methods, such as the
Smith-Waterman algorithm. We refer to [51] for more details. For Kinase, we
used the normalized Smith-Waterman scores as target–target similarities.
2.2 BLM: Bipartite Local Model
Bipartite Local Models (BLMs) [4] consider the drug–target interaction predic-
tion problem as a link prediction problem in bipartite graphs. As shown in
Fig. 2, the vertices in one of the vertex classes of the bipartite graph correspond
to drugs, whereas the vertices in the other vertex class correspond to targets.
Each edge eij of the graph corresponds to a known interaction between drug di
and target tj .
When predicting the likelihood of an unknown interaction eij between drug
di and target tj , the model computes two independent predictions that are
aggregated subsequently.
The first prediction is based on the relations between di and the targets.
Each target (except tj) is labeled as “1” or “0” depending on whether or not
there is a known interaction between di and the target. Then a model is trained
to distinguish between “1”-labeled and “0”-labeled targets. Subsequently, this
model is applied to predict the likelihood of the unknown interaction eij . This
first prediction for the likelihood of the interaction between drug di and target
tj is denoted by yˆ1(di, tj).
The second prediction, denoted by yˆ2(di, tj), is obtained in a similar fashion,
but instead of considering the interactions of drug di and labeling the targets,
the interactions of target tj are considered and drugs are labeled. The models
that make the first and second predictions are called local models.
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In order to obtain the final prediction of the BLM, we average the predictions
of the aforementioned local models:
yˆ(di, tj) =
yˆ1(di, tj) + yˆ2(di, tj)
2
(1)
Note that instead of averaging, other aggregation functions, such as minimum
or maximum are possible as well.
BLM is a generic framework in which various regressors or classifiers can be
used as local models. While Bleakley and Yamanishi [4] used support vector
machines with a domain-specific kernel, we propose to use a hubness-aware
regression technique, ECkNN, which is described in Section 2.4.
2.3 Predictions based on Weighted Profiles
One of the shortcomings of the BLM approach is that it does not handle the case
of “new” drugs and “new” targets. With “new” drug, we mean a drug d that
does not have any known interaction in the training data. In such cases, all the
targets are labeled as “0”, and no reasonable local model can be learned solely
from “0”-labeled targets. Similar problem arise in case of “new” targets as well.
In order to alleviate this problem, we use the weighted profile [51] approach to
obtain predictions for “new” drugs and “new” targets.
Given a “new” drug di, and a target tj , we predict the likelihood of the
interaction between di and tj as follows:
yˆ1(di, tj) =
∑
d′∈D\{di}
sim(di, d
′)i(d′, tj)∑
d′∈D\{di}
sim(di, d′)
(2)
where D denotes the set of all drugs, sim(di, d′) is the chemical similarity be-
tween drugs di and d
′ and i(d′, tj) indicates the presence or absence of interaction
between drug d′ and target tj among the known interactions (i.e., interactions
in the training set):
i(d′, tj) =
{
1 if there is a known interaction between d′ and tj
0 otherwise.
The intuition behind Eq. (2) is that similar drugs are likely to behave similarly
in terms of their interaction with a given target. Therefore, drugs are weighed
according to their similarity to the “new” drug d, and we calculate the weighted
average of the interaction indicators as prediction.
The case of “new” targets is analogous. Given a “new” target tj and a
drug di, the weighted profile approach can be used to calculate the prediction
for the likelihood of the interaction between di and tj as follows:
yˆ2(di, tj) =
∑
t′∈T \{tj}
sim(tj , t
′)i(di, t′)∑
t′∈T \{tj}
sim(tj , t′)
(3)
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where T denotes the set of all targets and sim(t, t′) is the genomic similarity
between targets t and t′.
Although the weighted profile approach is more general than BLM, in the
sense that it can be used for “new” drugs and targets as well, the predictions
of the weighted profile approach are less accurate than the predictions of BLM.
Therefore, we use the weighted profile approach only in case of new drugs and
targets, where the BLM approach does not produce reasonable predictions.
2.4 ECkNN: k-Nearest Neighbor Regression with Error
Correction
In the last decades, various regression schemes have been introduced, such as
linear and polynomial regression, support vector regression, neural networks,
etc. One of the most popular regression techniques is based on the k-nearest
neighbors: when predicting the numeric label on an instance x with k-nearest
neighbor regression, the k-nearest neighbors of x (i.e., k most similar instances
to x) are determined and the average of their labels is calculated as the predicted
label of x. In our case, instances may either correspond to drugs or targets,
depending on whether the first or the second prediction of the BLM is calculated.
While being intuitive and simple to implement, k-nearest neighbor regression
is well-understood from the point of view of theory as well, see e.g. [2], [3], [13],
and the references therein for an overview of the most important theoretical
results. These theoretical results are also justified by empirical studies: for
example, in their recent paper, Stensbo-Smidt et al. found that nearest neighbor
regression outperforms model-based prediction of star formation rates [30], while
Hu et al. showed that a model based on k-nearest neighbor regression is able to
estimate the capacity of lithium-ion batteries [19].
Despite all of the aforementioned advantages of k-nearest neighbor regres-
sion, one of its recently explored shortcomings has to be mentioned, namely, the
suboptimal performance in the presence of bad hubs. Intuitively, bad hubs are
instances that appear as nearest neighbors of many other instances, but have
substantially different labels from those instances. The presence of bad hubs
has been shown to be related to the intrinsic dimensionality of the data. This
means, roughly speaking, that bad hubs are expected in complex data, such as
drug–target interaction data. For a more detailed discussion, we refer to [7].
In order to alleviate the detrimental effect of bad hubs, we proposed an error
correction technique which is reviewed next. We define the corrected label yc(x)
of a training instance x as
yc(x) =

1
|Rx|
∑
xi∈Rx
y(xi) if |Rx| ≥ 1
y(x), otherwise
, (4)
where y(x) denotes the original (i.e., uncorrected) label of instance x, and Rx
is the set of “reverse neighbors”, i.e. the set of training instances that have
x as one of their k-nearest neighbors. In order to make predictions, k-nearest
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Figure 3: Example used to illustrate error correction. The real values next to
each instance xi denote the labels of the instances.
neighbor regression with error correction (ECkNN) uses the corrected labels.
Given a “new” (unlabeled) instance x′, its predicted label yˆ(x′) is calculated as
follows:
yˆ(x′) =
1
k
∑
xi∈N (x′)
yc(xi). (5)
where N (x′) denotes the set of nearest neighbors of x′.
Using the example in Fig. 3 we illustrate how the corrected labels are cal-
culated. In Fig. 3 training instances are denoted by circles. They are identified
by the symbols x1...x7. The numeric value (0 or 1) next to each instance shows
its label. In order to keep the example simple, we use k = 1 nearest neighbor
to calculate the corrected labels of training instances. In the figure, directed
edges point from each instance to its first nearest neighbor. We only present
the calculations for x4 and x5 as the procedure is similar in case of the other
instances as well. Concretely, the corrected labels of x4 and x5 are:
yc(x4) =
1
2
(1 + 1) = 1,
yc(x5) =
1
3
(0 + 0 + 1) = 0.33.
Whenever ECkNN predicts the label of a new instance, it uses the corrected
labels of the training instances (such as 1 and 0.33 in case of x4 and x5) instead
of the original labels (i.e., 0 and 1, respectively).
In our study, we used a publicly-available implementation of ECkNN from
the PyHubs library.2
2http://www.biointelligence.hu/pyhubs
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3 HLM: Hubness-aware Local Models
In this section, we develop our approach for drug–target interaction prediction.
Following subsections describe components of the method, such as the represen-
tation of drugs and targets and the projection-based ensemble.
3.1 Similarity-based Representation
The given drug–drug similarities allow us to represent drugs in terms of their
similarities to all the drugs. This means that the first, second, third... features
in the representation of drug d correspond to the similarity between d and the
first, second, third... drug of the dataset. When using this representation, we
say that drugs are represented in the similarity space. Given the target–target
similarity matrices, targets may be represented in an analogous way, i.e., using
their similarities to all the targets.
While the chemical and genomic similarities between drugs and targets, as
described in Section 2.1 are undoubtedly useful, various studies suggest that
interaction data (i.e. the known interactions between drugs and targets in our
case) may contain highly valuable information as well. For example, in the
domain of recommender systems, even a few ratings (i.e., “interactions” be-
tween customers and products) may be more informative than metadata about
users and products [27]. Therefore, additionally to the given drug–drug and
target–target similarities, we propose to compute drug–drug and target–target
similarities based on the known interactions (i.e., interaction in the training set).
In particular, using the interaction matrix, we calculate the Jaccard-similarity
between drugs as well as between targets. Thus the enhanced similarity-based
representation of a drug (or target, respectively) consists of its chemical (ge-
nomic) similarity to all the drugs (targets) and its interaction-based similarity
to all the drugs (targets). This is illustrated in Fig. 4.
3.2 Projection-based Ensemble
We propose to build a projection-based ensemble of BLMs as follows. Given
the enhanced similarity-based representation of drugs and targets, we select a
random subset of features and use only the selected features when training the
local models and making predictions. Denoting the size of the set of selected
features by FD and FT (for drugs and targets, respectively), the above procedure
first projects drugs into FD-dimensional, and targets into an FT -dimensional
subspace. Subsequently, these lower dimensional representations are used with
the prediction models.
The above process of random selection of features and making predictions
using the resulting lower-dimensional representation is repeated N -times. This
results in an ensemble of N prediction models. As each member of the ensemble
is constructed in the same way, their expected prediction accuracies will be
similar, therefore, we propose to average the predictions of the members of the
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Figure 4: Illustration of enhanced similarity-based representation of drugs and
targets
ensemble. Thus the final output of the ensemble is:
yˆ(di, tj) =
1
N
N∑
l=1
yˆ(l)(di, tj) (6)
where yˆ(l)(di, tj) it the prediction of the l-th BLM for the interaction between
drug di and target tj .
The projection-based ensemble is illustrated in Fig. 5 for N = 2 base pre-
diction models and the selection of FD = FT = 3 features from the enhanced
similarity-based representation.
In order to account for the presence of hubs, we propose to use ECkNN
as local model in each of the BLMs. The proposed approach is summarized
in Alg. 1.
4 Experimental Evaluation
We begin the experimental evaluation of our approach by the description of
the experimental settings. This is followed by comparison to well-known drug–
target interaction prediction techniques, and the detailed analysis of HLM. Sub-
sequently, we compare HLM to more recent drug-target interaction prediction
techniques and discuss biological feasibility of the predictions.
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Figure 5: Projection-based ensemble of BLMs using the enhanced similarity-
based representation of drugs and targets.
4.1 Experimental Settings
In order to assist reproducibility and comparability with published results, in
Sections 4.2–4.4 we used the wide-spread evaluation protocol of Bleakley and
Yamanishi [4], i.e., we used leave-one-interaction-out cross-validation3 on the
same datasets and evaluated the predictions in terms of Area Under ROC Curve
(AUC) and Area Under Precision-Recall Curve (AUPR).
According to the recent study of Pahikkala et al. [39], evaluating drug–
target interaction prediction techniques with leave-one-out cross-validation may
lead to overoptimistic results. Therefore we used interaction-based4 5 × 5-fold
cross-validation in the subsequent experiments in Section 4.5 when we com-
pared our approach with more recent drug–target prediction techniques, such as
net Laplacian regularized least squares (NetLapRLS) [44], BLM with neighbor-
based interaction-profile inferring (BLM-NII) [24] and a combination of weighted
nearest neighbor and Gaussian interaction profile kernels (WNN-GIP) [40].
We implemented the proposed approach in Python. We used the ECkNN
implementation from the publicly available PyHubs library and methods from
the NumPy machine learning library for the calculation of AUC and AUPR.
The results presented in in Sections 4.2–4.4 were obtained with k = 3 nearest
3Jaccard-similarities between drugs (and targets, resp.) were re-calculated in each iteration
of the cross-validation: when making prediction for the pair (d, t), Jaccard-similarities between
drugs were calculated using all the targets except t. Similarly, the Jaccard-similarities between
targets were calculated using all drugs except d.
4In each round of the cross-validation, the test set contains one fifth of all the drug–target
pairs.
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Algorithm 1 Hubness-aware local models
Require: Drug–Target interaction matrix I, Drug–drug similarity matrix SD,
Target–target similarity matrix ST , number of nearest neighbors k, ensemble
size N , number of selected features FD, FT
Ensure: Likelihood of drug–target interactions
1: D ← enhanced similarity-based representations of drugs
2: T ← enhanced similarity-based representations of targets
3: for l = 1 . . . N do
4: D′ ← random sample of D with FD features
5: T ′ ← random sample of T with FT features
(Only features of D and T are sampled, all the drugs/targets are kept.)
6: Predict interaction scores with BLM using ECkNN as local model and
D′ and T ′ as the representation of drugs and targets respectively.
(Use the weighted profile approach for predictions for “new”
drugs/targets.)
7: end for
8: Aggregate the predictions that were made in each execution of the loop
neighbors. However, we note that we also tried other settings of this parameter,
such as k = 5, which lead to similar results. We used implementations of Net-
LapRLS, BLM-NII and WNN-GIP from the publicly available PyDTI software
library.5
4.2 Comparison with Wide-Spread Drug–Target Interac-
tion Prediction Techniques
In our first experiment, we compared the performance of our approach, HLM,
with prominent drug–target interaction prediction techniques from the litera-
ture. In particular, we used Kernel-Regression Method (KRM) [51], Bipartite
Local Models (BLM) [4] and the weighted profile approach (WP) as baselines.
In this experiment we set the size of the ensemble to N = 1 and the number
of selected features was set to the number of all the available features, i.e.,
the enhanced similarity-based representation was used with the local models,
without further projection to a lower-dimensional space.
The results are summarized in Tab. 2. As one can see, our approach, HLM
outperformed its competitors both in terms of AUC and AUPR.
4.3 The Effect of Hubness-aware Error Correction
In order to examine the effect of hubness-aware error correction, we predicted
drug-target interactions without error correction as well. All the experimental
settings were the same as in the previous experiment with the only exception
that we used simple k-nearest neighbor regressors instead of ECkNN as local
5https://github.com/stephenliu0423/PyDTI
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Table 2: The performance of our approach, HLM, and other drug–target inter-
action prediction techniques from the literature. The ensemble size in HLM is
set to N = 1.
Dataset Method AUC AUPR
(in %) (in %)
Enzyme HLM 98.4 92.9
BLM 97.3 84.1
KRM 96.7 83.1
WP 95.3 73.2
Ion Channel HLM 98.5 91.0
BLM 97.0 77.9
KRM 96.9 77.8
WP 96.4 77.0
GPCR HLM 96.8 74.4
BLM 95.3 66.7
KRM 94.7 66.4
WP 89.0 42.9
NR HLM 95.5 68.1
BLM 85.8 60.0
KRM 86.7 61.0
WP 80.5 39.4
Table 3: The performance of the proposed approach with and without hubness-
aware error correction (EC).
Dataset AUC AUPR
(in %) (in %)
Enzyme HLM (with EC) 98.4 92.9
predictions without EC 97.4 88.2
Ion Channel HLM (with EC) 98.5 91.0
predictions without EC 97.6 89.3
GPCR HLM (with EC) 96.8 74.4
predictions without EC 95.0 70.7
NR HLM (with EC) 95.5 68.1
predictions without EC 89.9 58.2
models. The results are shown in Tab. 3. The results clearly indicate that error
correction indeed contributes to accurate predictions.
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Figure 6: The effect of the ensemble size on the prediction performance in
case of the proposed approach (HLM, solid line) and the predictions without
error correction (dotted line). Although increasing the ensemble size leads to
performance improvements in both cases, we note that in case of HLM, the
performance converges to a higher accuracy as measured by both AUC and
AUPR.
4.4 The Effect of the Ensemble Size
Next we examined the effect of the ensemble size (N) on the prediction per-
formance. We set the number of selected features FT = FD = 50 and varied
the number of base models (N) in the ensemble. Fig. 6 shows detailed results
for two datasets, GPCR and ion channel, however, we note that we observed
similar trends in case of the other two datasets as well.
First of all, we could observe that the projection-based ensemble technique
described in Section 3.2 systematically increases the performance. For example,
on the GPCR dataset in case of N ≈ 100 base models the AUPR of predictions
increased from 74.4 % to 79.4 % compared with the case of using all the available
features within one prediction model used in the previous experiments. For the
ion channel dataset, the AUPR increased from 91 % to 93.9 %.
In order to examine the interaction between the projection-based ensemble
technique and hubness-aware error correction, we also built ensembles using k-
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nearest neighbor regression without error correction as local models. All the
other experimental settings were the same as in case of the proposed approach.
In both cases (i.e., with and without error correction) the performance improves
with increasing ensemble size. However, in case of the proposed approach the
performance converges to a higher accuracy as measured by both AUC and
AUPR. This indicates that error correction and the projection based ensemble
technique are complementary to each other, i.e., both of them are essential for
accurate predictions.
4.5 Comparison with Recent Drug–Taget Interaction Pre-
diction Techniques
In order to illustrate that our approach, HLM, is able to outperform recent drug–
target interaction prediction techniques as well, we performed experiments with
HLM with N = 25 base prediction models. Other hyperparameters of HLM
were learned via grid-search in internal 5-fold cross-validation on the training
data. In particular: the number of nearest neighbors for the local model ECkNN
and the number of selected features, were chosen from {3, 5, 7} and {10, 20, 50}.
Hyperparameters of the baselines were learned similarly. In particular: for
BLM-NII, the max function was used to generate final predictions and the
weight α for the combination of structural and collaborative similarities was
chosen from {0.0, 0.1, . . . , 1.0}. In WNN-GIP, the decay hyperparameter T
was chosen from {0.1, 0.2, . . . , 1.0} and the weight α for combination of struc-
tural and collaborative similarities was chosen from {0.0, 0.1, . . . , 1.0}. The
hyperparameters6 of NetLapRLS, were chosen from {10−6, 10−5, . . . , 102}.
As the results in Tab. 4 show, our approach, HLM, outperforms NetLapRLS,
BLM-NII and WNN-GIP in all the cases, except the NR dataset, where its per-
formance was similar to that of BLM-NII (the difference statistically insignif-
icant). We note, however, that NR is an exceptionally small dataset, there-
fore, the results obtained on NR are likely to be less stable compared to other
datasets.
We performed paired t-test at significance level p = 0.01 in order to check if
the differences between the best-performing approach (i.e., HLM in almost all
the cases) and the other techniques are statistically significant or not. In Tab. 4
and Tab. 5, asterisk (*) denotes the cases where the difference was found to be
statistically significant. As one can see, in the vast majority of the cases our
approach, HLM, outperformed its competitors statistically significantly.
We also evaluated the predictions in terms of precision, recall and accuracy.
In order to do that, we ranked drug–target pairs according to their predicted
interaction scores and considered the top-ranked 5% of the interactions as the
ones that are predicted to interact (predicted positives). The rest of the drug–
target pairs were considered as the predicted non-interacting drug–target pairs
(predicted negatives). As the results in Tab. 5 show, our approach, HLM,
6β = βdrug = βtarget and γ = γdrug = γtarget
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Table 4: The performance (AUC, AUPR) of our approach, HLM, and recent
drug–target interaction prediction techniques.
Dataset Method AUC AUPR
(in %) (in %)
Enzyme HLM 96.6 83.2
BLM-NII 96.6 62.8*
NetLapRLS 95.9* 78.4*
WNN-GIP 94.5* 70.8*
Ion Channel HLM 98.0 86.7
BLM-NII 96.0* 62.6*
NetLapRLS 96.6* 82.7*
WNN-GIP 94.7* 66.3*
GPCR HLM 94.7 68.6
BLM-NII 92.9* 38.7*
NetLapRLS 91.0* 58.0*
WNN-GIP 92.8* 51.3*
NR HLM 86.4 57.6
BLM-NII 87.9 54.3
NetLapRLS 81.0* 42.8*
WNN-GIP 86.2 55.0
Kinase HLM 93.1 61.5
BLM-NII 70.2* 8.8*
NetLapRLS 91.3* 57.7*
WNN-GIP 52.8* 6.2*
outperformed its competitors in terms of precision, recall and accuracy as well.7
4.6 Prediction of New Interactions
In this section, by examining some of the highly scored interactions in detail,
we illustrate that HLM not only achieves high accuracy in terms of AUC and
AUPR, but the predictions are biologically feasible as well.
We begin this discussion by noting that the drug–target interactions con-
tained in the Enzyme, Ion Channel, G-protein coupled receptors (GPCR) and
Nuclear Receptors (NR) datasets were extracted from the Kyoto Encyclopedia
of Genes and Genomes8 (KEGG) several years ago and, in order to allow for
comparison of prediction techniques, they have been kept unchanged. Mean-
while, additional drug–target interactions have been validated chemically and
7On the Enzyme data the difference in accuracy was in the second decimal place (not shown
in Tab. 5), however, it was systematic throughout the 5 × 5 = 25 rounds of cross-validation,
therefore HLM was found to outperform its competitors significantly.
8http://www.kegg.jp/
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Table 5: Precision, recall and accuracy of our approach, HLM, and recent drug–
target interaction prediction techniques.
Dataset Method Precision Recall Accuracy
(in %) (in %) (in %)
Enzyme HLM 17.9 90.4 95.8
BLM-NII 17.7* 89.7* 95.8*
NetLapRLS 17.6* 89.1* 95.8*
WNN-GIP 17.3* 87.8* 95.7*
Ion Channel HLM 61.8 89.3 97.7
BLM-NII 51.4* 74.3* 96.7*
NetLapRLS 57.7* 83.4* 97.3*
WNN-GIP 59.1* 85.5* 97.5*
GPCR HLM 45.8 76.7 96.6
BLM-NII 35.7* 59.9* 95.6*
NetLapRLS 39.3* 65.7* 95.9*
WNN-GIP 43.7* 73.1* 96.4*
NR HLM 64.3 50.8 95.0
BLM-NII 56.3* 44.2* 94.2*
NetLapRLS 49.1* 38.3* 93.5*
WNN-GIP 63.7 50.5 94.9
Kinase HLM 57.4 56.2 95.6
BLM-NII 7.7* 7.6* 90.7*
NetLapRLS 57.3 56.1 95.6
WNN-GIP 6.4* 6.2* 90.5*
the results have been uploaded to databases, such as KEGG [20], DrugBank [41]
or Matador [38].
Therefore, in order to demonstrate that our approach is able to predict
new interactions, we trained our approach, HLM, as well as its competitors,
BLM-NII, NetLapRLS and WNN-GIP using all the interactions of the origi-
nal datasets, and ranked the non-interacting drug–target pairs of the original
datasets according to their predicted interaction scores. For simplicity, we use
the term predicted new interactions for the top-ranked 20 drug–target pairs. We
say that a predicted new interaction is validated if it is included in the current
version of KEGG, DrugBank or Matador.
Our approach, HLM, had the overall best performance in terms of the num-
ber of validated interactions compared with BLM-NII, NetLapRLS and WNN-
GIP. For example, on the Ion Channel and NR datasets, HLM was able to
predict 12 and 8 validated interactions, whereas none of its competitors was
able to predict more than 6 validated interactions on these datasets. For En-
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Table 6: Top 20 new interactions predicted by our approach, HLM, on the
Enzyme dataset.
Drug Target Validated Also predicted by
1 D00542 hsa:1571 yes BLM-NII, NetLapRLS, WNN-GIP
2 D00437 hsa:1559 yes BLM-NII, NetLapRLS, WNN-GIP
3 D00139 hsa:1543 yes BLM-NII, NetLapRLS, WNN-GIP
4 D00574 hsa:1589 yes NetLapRLS, WNN-GIP
5 D00691 hsa:5152 no NetLapRLS
6 D00410 hsa:1543 yes BLM-NII, NetLapRLS, WNN-GIP
7 D00410 hsa:1583 yes NetLapRLS
8 D00437 hsa:1585 yes BLM-NII
9 D00691 hsa:8654 no NetLapRLS
10 D00528 hsa:1549 yes BLM-NII, NetLapRLS, WNN-GIP
11 D00410 hsa:1585 yes BLM-NII
12 D00449 hsa:5742 no –
13 D00126 hsa:246 yes –
14 D00126 hsa:247 yes –
15 D03670 hsa:1579 no BLM-NII, NetLapRLS, WNN-GIP
16 D05458 hsa:4128 yes –
17 D00691 hsa:5150 yes –
18 D03670 hsa:51302 no NetLapRLS
19 D03670 hsa:9420 no NetLapRLS, WNN-GIP
20 D00691 hsa:50940 no NetLapRLS
zyme and GPCR datasets, new interactions9 are shown in Tab. 6 and Tab. 7.
The last columns of these tables show if the same interaction was predicted by
other approaches.
Most notably, numerous validated interactions (in bold) were only predicted
by our approach, HLM, including the interactions between Ibuprofen (D00126)
and arachidonate 15-lipoxygenase (hsa:246) and its second type (hsa:247); as
well as the interaction between Phentermine (D05458) and monoamine oxidase
A (hsa:4128); and the interaction between Dyphylline (D00691) and phosphodi-
esterase 7A (hsa:5150). On the GPCR dataset, only our approach was able to
predict the validated interaction between Theophylline sodium acetate (D01712)
and adenosine A2b receptor (hsa:136), as well as the interaction between Loxap-
ine (D02340) and dopamine receptor D1 (hsa:1812).
9For the resolution of drug and target identifiers, see http://www.kegg.jp/
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Table 7: Top 20 new interactions predicted by our approach, HLM, on the
GPCR dataset.
Drug Target Validated Also predicted by
1 D00283 hsa:1814 yes BLM-NII, NetLapRLS, WNN-GIP
2 D00437 hsa:152 no NetLapRLS, WNN-GIP
3 D00095 hsa:155 yes BLM-NII
4 D00255 hsa:152 yes NetLapRLS
5 D00227 hsa:136 no WNN-GIP
6 D00503 hsa:1816 no –
7 D01712 hsa:136 yes –
8 D02340 hsa:1812 yes –
9 D02354 hsa:1814 no –
10 D04625 hsa:154 yes BLM-NII
11 D00283 hsa:1132 yes WNN-GIP
12 D03621 hsa:1132 no WNN-GIP
13 D02358 hsa:154 yes BLM-NII
14 D00494 hsa:1815 no –
15 D02147 hsa:153 yes BLM-NII
16 D02354 hsa:1816 no –
17 D00503 hsa:3356 no BLM-NII
18 D02614 hsa:154 no BLM-NII
19 D00513 hsa:152 no NetLapRLS, WNN-GIP
20 D00513 hsa:3363 no WNN-GIP
5 Conclusion and Outlook
In this study, we considered the drug–target interaction prediction problem
which has important applications in understanding the mechanisms of how drugs
effect, drug repositioning and prediction of adverse effects. We proposed an
extension of BLM, one of the most prominent drug-target prediction models.
In particular, we proposed to represent drugs and targets in a multi-modal
similarity space, used ECkNN, a hubness-aware regression approach as local
model in BLM and built projection-based ensembles. We called the resulting
approach HLM (hubness-aware local models).
We performed experiments on widely-used publicly-available datasets, the
results of which show that our approach is superior to other drug-target predic-
tion approaches from the literature such as BLM, KRM, BLM-NII, NetLapRLS
and WNN-GIP. We examined the effect of hubness-aware error correction and
the ensemble size and found that both of these techniques are essential for high
accuracy. Subsequently, we demonstrated that our approach is able to predict
new drug–target interactions.
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